Galectin Therapeutics (GALT) Research & Development (2010 - 2026)

Galectin Therapeutics' Research & Development history runs 17 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• On a quarterly basis, Research & Development fell 65.6% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $10.0 million, a 71.33% decrease from a year earlier, with the FY2025 full-year figure at $14.3 million, down 60.93% from the prior year.
• Research & Development advanced to $2.2 million in Q1 2026 per GALT's latest filing, from $1.9 million in the prior quarter.
• Across five years, Research & Development topped out at $11.1 million in Q4 2024 and bottomed at $1.9 million in Q4 2025.
• The 5-year median for Research & Development is $7.7 million (2023), against an average of $6.9 million.
• Across the five-year window, Research & Development soared 64.48% in 2022 and sank 82.6% in 2025, its largest moves.
• Year by year, Research & Development stood at $9.0 million in 2022, then dropped by 8.65% to $8.2 million in 2023, then jumped by 35.01% to $11.1 million in 2024, then sank by 82.6% to $1.9 million in 2025, then advanced by 15.42% to $2.2 million in 2026.
• Per Business Quant, the three latest GALT Research & Development figures stand at $2.2 million (Q1 2026), $1.9 million (Q4 2025), and $2.6 million (Q3 2025).